"On schedule"... As a long-time BNC investor, product development that is on schedule, is "new" news to me!
Even if it is just a "confirmation" from Endo that their "current estimate" remains the same for the timing of Urocidin's Phase 3b study completion & final data collection for primary endpoints (based on one-year data).
We are nearing the halfway point of this clinical trial and dates could have already shifted as a timeline estimate.
This is definitely one of/ or the most significant future event for Bioniche regarding its course and valuation. And, at the upper-end of importance even for Endo, when you consider the strategic importance Urocidin is to Endo's future oncology focus/strategy and $ investment they have made for this trial/licensing agreement.
Art, thank you for posting the reply from Endo's IR. rg